Yousif Capital Management LLC Sells 2,868 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Yousif Capital Management LLC lowered its position in Pediatrix Medical Group, Inc. (NYSE:MDFree Report) by 7.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,017 shares of the company’s stock after selling 2,868 shares during the period. Yousif Capital Management LLC’s holdings in Pediatrix Medical Group were worth $432,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of MD. Eagle Bay Advisors LLC boosted its stake in shares of Pediatrix Medical Group by 122.5% during the 2nd quarter. Eagle Bay Advisors LLC now owns 1,595 shares of the company’s stock worth $34,000 after acquiring an additional 878 shares during the last quarter. Royal Bank of Canada lifted its position in Pediatrix Medical Group by 97.3% during the third quarter. Royal Bank of Canada now owns 2,166 shares of the company’s stock valued at $35,000 after purchasing an additional 1,068 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Pediatrix Medical Group by 90.6% during the first quarter. Tower Research Capital LLC TRC now owns 2,262 shares of the company’s stock valued at $34,000 after purchasing an additional 1,075 shares in the last quarter. Quarry LP grew its holdings in Pediatrix Medical Group by 88.5% during the second quarter. Quarry LP now owns 2,586 shares of the company’s stock valued at $37,000 after purchasing an additional 1,214 shares during the period. Finally, Counterpoint Mutual Funds LLC purchased a new stake in Pediatrix Medical Group in the third quarter worth about $84,000. Institutional investors own 96.89% of the company’s stock.

Insider Transactions at Pediatrix Medical Group

In related news, CEO James D. Swift sold 5,764 shares of the business’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $9.58, for a total value of $55,219.12. Following the sale, the chief executive officer now owns 90,874 shares in the company, valued at $870,572.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Stock Performance

MD opened at $9.50 on Wednesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.20 and a current ratio of 1.20. The stock has a market capitalization of $798.19 million, a price-to-earnings ratio of 8.41, a PEG ratio of 0.85 and a beta of 1.57. The company has a fifty day moving average of $9.33 and a 200 day moving average of $11.53. Pediatrix Medical Group, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $17.30.

Pediatrix Medical Group (NYSE:MDGet Free Report) last issued its earnings results on Thursday, November 2nd. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.11). Pediatrix Medical Group had a return on equity of 11.70% and a net margin of 4.65%. The firm had revenue of $506.60 million during the quarter, compared to the consensus estimate of $507.59 million. During the same period last year, the firm posted $0.37 earnings per share. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 1.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MD has been the subject of a number of recent research reports. StockNews.com initiated coverage on Pediatrix Medical Group in a research note on Thursday, October 5th. They set a “hold” rating for the company. Truist Financial decreased their price objective on shares of Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating on the stock in a research report on Wednesday, October 11th. Finally, UBS Group began coverage on Pediatrix Medical Group in a research note on Thursday, November 30th. They issued a “neutral” rating and a $9.50 price target for the company.

Check Out Our Latest Research Report on MD

About Pediatrix Medical Group

(Free Report)

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Read More

Institutional Ownership by Quarter for Pediatrix Medical Group (NYSE:MD)

Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.